Navigation Links
BellBrook Labs Launches Second Generation Transcreener EPIGEN Methyltransferase Assay to Acclerate Epigenetic Drug Discovery
Date:8/15/2013

Madison, WI (PRWEB) August 15, 2013

Methyltransferases are key players in epigenetic control of gene expression and have become the targets of intensive public and private drug discovery efforts. To accelerate these efforts, BellBrook developed the Transcreener EPIGEN Methyltransferase Assay, a fluorescent SAH detection assay with the sensitivity needed to detect any methyltransferase at physiological SAM concentrations, and the robustness required for industrial HTS. Since its introduction in 2011, the EPIGEN assay has been validated on all of the major instrument platforms and adopted by industrial and academic laboratories worldwide. Now, in response to customer feedback, we have reduced the number of components and simplified the protocol. The performance and response of the simplified assay is identical to the original kit; it contains pre-mixed detection components, so assay set-up is simpler and results are more reproducible.

By utilizing its expertise in HTS assay development, the BellBrook team is able to offer universal, fluorescence based detection of any methyltransferase enzyme that uses SAM as a methyl donor. This approach avoids the complexities and difficulties of detecting specific methylated products. The EPIGEN assay relies on enzymatic conversion of SAH to AMP, which is then detected using the Transcreener® AMP/GMP Assay. It provides robust activity measurements even with very low levels of SAM, while still offering the outstanding deck and signal stability of BellBrook’s Transcreener® Assays. Similar EPIGEN assays are being developed to screen additional epigenetic enzymes, including Histone Acetyltransferases (HATs).

About BellBrook Labs
BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions for enzymes and phenotypic assays. The company’s Transcreener® HTS enzyme assays, used by all of the major pharmaceutical companies, make it easy to screen thousands of different enzymes, including validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11024850.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
2. BellBrook Labs Launches Four New Turn-Key Methyltransferase Assay Kits
3. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
4. BellBrook Labs Strengthens Ties with Cambio for Distribution of Transcreener HTS Assays in the UK
5. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
6. 23andMe Launches First National TV Campaign
7. Pearly Whites Laser Dentistry Launches Ground Breaking Cavity Prevention Program that Can Lower Decay Rates by 74%
8. Dr. Gray Bailey Launches Ground Breaking Cavity Prevention Program That Can Lower Tooth Decay Rates by 74%
9. ASAE Launches New Book Guiding Association Professionals on How to Use Research for Results
10. Pure Transplant Solutions Launches Crowdfunding Campaign for Its Novel Technology Poised to Change the Future of Organ Transplantation
11. SoundConnect Launches Innovative Partner Incentive Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
Breaking Biology News(10 mins):